iNtRON Biotechnology, Inc.

KOSDAQ:A048530 Stock Report

Market Cap: ₩185.9b

iNtRON Biotechnology Past Earnings Performance

Past criteria checks 0/6

iNtRON Biotechnology's earnings have been declining at an average annual rate of -36.6%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been declining at an average rate of 20.6% per year.

Key information

-36.6%

Earnings growth rate

-37.0%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-20.6%
Return on equity-5.4%
Net Margin-55.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24
We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Recent updates

iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

Nov 15
iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03
We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24
We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

Feb 28
Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 31
iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05
iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

Dec 10
What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Nov 26
iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Revenue & Expenses Breakdown

How iNtRON Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A048530 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248,615-4,8165,0853,464
30 Jun 249,078-6,0914,5453,285
31 Mar 249,422-8,5184,5703,057
31 Dec 239,585-9,6954,9463,174
30 Sep 238,302-9,5604,8513,072
30 Jun 239,460-8,6525,6703,057
31 Mar 2310,0705,3726,8083,183
31 Dec 2214,0075,7126,7963,312
30 Sep 2219,6818,0156,7163,086
30 Jun 2224,56911,7086,5483,598
31 Mar 2229,5877,1496,8723,681
31 Dec 2129,3089,7287,0433,553
30 Sep 2133,00214,9487,5854,229
30 Jun 2132,29314,9487,6113,890
31 Mar 2147,89916,8866,5933,634
31 Dec 2045,43314,9486,1923,489
30 Sep 2035,8317,6775,2783,082
30 Jun 2030,6832,9155,2332,843
31 Mar 209,851-3,3964,9442,766
31 Dec 198,347-3,1874,8362,252
30 Sep 1919,95210,8765,8062,382
30 Jun 1919,9979,2685,7282,922
31 Mar 1919,9889,7395,5273,026
31 Dec 1820,5848,7115,6843,660
30 Sep 189,991-7,0184,6244,033
30 Jun 1810,345-2,8444,7983,871
31 Mar 1810,915-10,0564,9263,699
31 Dec 1710,963-8,7344,8593,501
30 Sep 1711,000-5,2714,9935,085
30 Jun 1710,959-5,4484,9204,218
31 Mar 1710,296-2,1464,9423,727
31 Dec 1610,222-2,2524,8583,106
31 Dec 1511,8351,5584,387428

Quality Earnings: A048530 is currently unprofitable.

Growing Profit Margin: A048530 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A048530 is unprofitable, and losses have increased over the past 5 years at a rate of 36.6% per year.

Accelerating Growth: Unable to compare A048530's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A048530 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A048530 has a negative Return on Equity (-5.39%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:40
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iNtRON Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sangsoo KimGoldman Sachs